Novo Nordisk Lays Out Obesity Commercial Strategy, Ahead of Liraglutide FDA Submission
This article was originally published in The Pink Sheet Daily
Executive Summary
Reimbursement and sales strategy for liraglutide 3 mg to treat obesity, which the pharma hopes to launch in 2015, are a focus as the pharma laid out its long-term plans in an analyst meeting on Dec. 3. It suggested payers, who aren’t embracing new obesity drugs, could try patients on the drug for a trial period and proceed only with the best responders.